About Us

Precision Virologics, Inc.

Unique Vector Engineering Technology

 

Our engineered adenoviruses are capable of achieving extended and selective gene expression in vivo. The unique capacities feasibilize an expanded range of gene therapy and vaccine interventions to achieve biologically precise outcomes.

Precision Virologics Infrastructure

 

Cortex district provides a vibrant and growing culture of entrepreneurship, including wet labs and Cores. BioSTL provides networking within region pursuant to expertise and funding. Washington University Center for Drug Discovery provides developmental expertise.

Precision Virologics Leveraging

 

NIH provides specific mechanisms to support GMP production and toxicologic study of virus-based investigational agents. NIH/FDA grants provide non-dilutive support for translational development. CSO/Founder has unpreceded record of NIH support for viral agents translated to human trials

Management Team

David T. Curiel, MD, PhD
CSO and Founder

David T. Curiel, MD, PhD is a Professor of Medicine in the Department of Radiation Oncology at Washington University School of Medicine and the Director of the Biologic Therapeutics Center. He has been continuously funded by the NIH for more than 25 years. He is an expert in gene therapy and adenovirus biology, having authored more than 600 scientific articles on these subjects including Editorship of the definitive “Adenoviral Vectors for Gene Therapy“.

Daniel Katzman
CEO

Mr. Katzman has over twenty years of experience in the life sciences industry. Mr. Katzman supervised clinical trials, regulatory approval, intellectual property and marketing. Additionally, he has been granted four US patents, has led a pivotal, multi-center Phase III study and has obtained FDA approval for a drug-device combination product which included an NDA and a 510(k). Mr. Katzman received his graduate degree in Biochemistry from Universidad Nacional de La Plata, Argentina.

Precision Virologics Expert Advisors

Michael Diamond, MD, PhD

Developer of  alphavirus virus model for vaccine analysis. Professor and Director Center for Human Immunology and Immunotherapy, Wash U School of Medicine.

Dan Hoft, MD, PhD

Chair, Division of Infectious Diseases, SLU. Principal Investigator at SLU’s Vaccine Treatment & Evaluation Unit.

Sarah George, MD

Expert in Flavivirus (Zika, Chikungunya, Dengue). PI for an NIH sponsored Zika Vaccine trial. Associate Professor of Infectious Diseases, SLU.

Xiaoxia Cui, PhD

Director of the Genome Engineering and iPSC Center (GEiC). Assistant Professor, Department of Genetics, Washington University in St. Louis.